Paris Course On Revascularization In Brief
This article was originally published in The Gray Sheet
Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...
You may also be interested in...
Conor Medsystems expects to begin enrolling a 1,700-patient, U.S. pivotal trial for itsCoStar paclitaxel-eluting, cobalt-chromium coronary stent in the next few weeks
Cordis aims to expand the U.S. shelf life of its Cypher sirolimus-eluting stent after resolving manufacturing issues cited by FDA in an April 2004 warning letter
Johnson and Johnson/Cordis' European RAVEL study data sets a high standard for other drug-coated stent developers, including no restenosis at six-month follow-up.